Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial

Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial

Abstract Background Most subsequent new primary or recurrent melanomas might be self-detected if patients are trained to systematically self-examine their skin and have access to timely medical review (patient-led surveillance). Routinely scheduled clinic visits (clinician-led surveillance) is resou...

Full description

Bibliographic Details
Main Authors: Deonna M. Ackermann, Amelia K. Smit, Monika Janda, Cathelijne H. van Kemenade, Mbathio Dieng, Rachael L. Morton, Robin M. Turner, Anne E. Cust, Les Irwig, Jolyn K. Hersch, Pascale Guitera, H. Peter Soyer, Victoria Mar, Robyn P. M. Saw, Donald Low, Cynthia Low, Dorothy Drabarek, David Espinoza, Jon Emery, Peter Murchie, John F. Thompson, Richard A. Scolyer, Anthony Azzi, Alister Lilleyman, Katy J. L. Bell
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Trials
Subjects:
Melanoma
Cancer surveillance
Early detection of cancer
Self-examination
Teledermoscopy
Telehealth
Online Access:https://doi.org/10.1186/s13063-021-05231-7

Internet

https://doi.org/10.1186/s13063-021-05231-7

Similar Items